[Effect of aminoguanidine on oxidative modification of proteins in experimental diabetes mellitus in rats].
It was shown that administration of aminoguanidine is accompanied by a decrease of the content of nitric oxide stable metabolites, as well as protein carbonyl groups in leukocytes and blood plasma in diabetic and control animals. Aminoguanidine is proposed to be used for pharmacological correction of NO biosynthesis. Aminoguanidine, being the selective iNOS inhibitor, antioxidant and the factor eliminating post-translational protein nitrozylation and oxidative modification, weaken the toxic effects of NO and positively modulates the pathological state caused by NO hyperproduction.
Brodiak
I V
IV
Sybirna
N O
NO
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006146:Guanidines / Q000494:pharmacology*; D008297:Male; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000187:drug effects*; D011506:Proteins / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
D017127:Glycation End Products, Advanced; D006146:Guanidines; D011506:Proteins; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; C004479:pimagedine